ArticleScientific reports2024
The burden of schizophrenia in the Middle East and North Africa region, 1990-2019.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-adherence with the treatment regimen and its associated factors among patients with schizophrenia in Sub-Saharan Africa: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Clinical and Demographic Characteristics in Schizophrenia Patients with and without a History of Taking Long-acting Injectable Antipsychotics: A Comparative Cross-sectional Study.Journal of research in pharmacy practice · 2026Article
- Mapping the Scientific Landscape of Schizophrenia Genetics (2020-2025): A Bibliometric and Scientometric Study of Global Trends and Collaborations.Brain and behavior · 2026Article
- Global, regional, and national burden of schizophrenia: epidemiological trends, decomposition, joinpoint analysis, and projections to 2036 based on GBD 2021.Frontiers in psychiatry · 2026Article
- Trends and future burden of schizophrenia in youth across G20 countries: a systematic analysis of the global burden of disease 2021 study.BMC psychiatry · 2025Article
- Exploring Medication Errors with Antipsychotics in Saudi Arabia: Insights from a Nationwide Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Psychometric Properties of the Arabic Version of the Pictorial Empathy Test for Assessing Affective Empathic Reactions in Patients with Schizophrenia.Healthcare (Basel, Switzerland) · 2025Article
- Validation of the shortest version of the eating attitude test (EAT-7) as a screening tool for disordered eating in patients with first-episode schizophrenia.Journal of eating disorders · 2025Article
- Trends in incidence, prevalence, and disability-adjusted life years of schizophrenia in China from 1990 to 2021, with projections for 2022-2050.Frontiers in psychiatry · 2025Article
- GBD: incidence rates and prevalence of anxiety disorders, depression and schizophrenia in countries with different SDI levels, 1990-2021.Frontiers in public health · 2025Article
- Global trends and health inequalities in mental disorders among older adults: a comprehensive analysis using global burden of disease 2021 data.Frontiers in public health · 2025Article
- Age-period-cohort analysis of schizophrenia incidence in China and Japan from 1990 to 2021: long-term trends and risk changes.Frontiers in psychiatry · 2025Article
- Schizophrenia and Heart Health: Are Antipsychotics a Friend or Foe?Journal of personalized medicine · 2024Article
- Psychometric Properties and Factor Structure of the Arabic Translation of the Brief Negative Symptom Scale.Complex psychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Schizophrenia ranks as the third-most common cause of disability among mental disorders globally. This study presents findings on the prevalence, incidence and years lived with disability (YLDs) as a result of schizophrenia in the Middle East and North Africa (MENA), stratified by age, sex and sociodemographic index (SDI). We collected publicly accessible data from the Global Burden of Disease (GBD) study 2019. This study reports the burden of schizophrenia, from 1990 to 2019, for the 21 countries that comprise MENA. In 2019, MENA exhibited an age-standardised point prevalence of 248.2, an incidence rate of 14.7 and an YLD rate of 158.7 per 100,000, which have not changed substantially between 1990 and 2019. In 2019, the age-standardised YLD rate was highest in Qatar and lowest in Afghanistan. No MENA countries demonstrated noteworthy changes in the burden of schizophrenia from 1990 to 2019. Furthermore, in 2019, the highest number of prevalent cases and the point prevalence were observed among those aged 35-39, with a higher prevalence among males in almost all age categories. Additionally, in 2019, the age-standardised YLD rates in MENA were below the worldwide average. Finally, there was a positive correlation between the burden of schizophrenia and the SDI from 1990 to 2019. The disease burden of schizophrenia has remained relatively stable over the past thirty years. Nevertheless, as the regional life-expectancy continues to increase, the burden of schizophrenia is also expected to rise. Therefore, early planning for the increase in the burden of the disease is urgently needed in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.